PhRMA's new re­port counts each can­cer drug in the US pipeline, which has now swelled to over 1,000 in the clin­ic

Can­cer drugs are crowd­ing in to an al­ready cramped pipeline this year, with hun­dreds of im­muno-on­col­o­gy hope­fuls now tak­ing a shot at clin­i­cal test­ing. That’s ac­cord­ing to a new can­cer re­port from PhRMA, which count­ed 1,120 on­col­o­gy drugs in the clin­ic so far this year — a mas­sive in­crease from pre­vi­ous years — and that’s just in the US.

For per­spec­tive, there were on­ly 836 can­cer ther­a­pies count­ed by PhRMA in 2015, which means the pipeline has swelled 34% in less than three years. The or­ga­ni­za­tion on­ly count­ed drugs al­ready in the clin­ic or await­ing re­view from the FDA. That means there’s a sig­nif­i­cant back­log of ther­a­pies in pre­clin­i­cal de­vel­op­ment, wait­ing to el­bow their way in­to the fray.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.